We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were ...

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused ...

Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...

Non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, is projected to become the leading cause of liver ...

Although NASH can lead to severe liver scarring (cirrhosis), inflammation and loss of function, there are no approved treatments for the disease. Researchers don’t even know for certain what ...

The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday. NASH ...

Developers targeting a liver disease called nonalcoholic steatohepatitis (NASH) are among the notable outperformers in the biopharma space this year, as Madrigal Pharmaceuticals (NASDAQ ...

The trial uses the earlier nomenclature of NASH and nonalcoholic fatty liver disease (NAFLD). An international consensus group has since changed these terms to metabolic dysfunction–associated ...